Special Issue

Genes and Gene Therapies in Chronic Renal Disease

Message from the Guest Editor

This Special Issue highlights the transformative role of molecular and medical genetics in enhancing the understanding, diagnosis, and treatment of patients with chronic renal disease. Recent advancements have revolutionized our ability to treat chronic kidney disease by identifying the numerous molecular mechanisms that contribute to the development of polycystic kidney disease, glomerulosclerosis, tubulointerstitial kidney disease, and congenital anomalies of the kidney and urinary tract. Cutting-edge technologies, including CRISPR-Cas9 and other gene editing tools, offer promising personalized approaches for the treatment of hereditary causes of renal disease. Meanwhile, recent progress in the development of small-molecule, RNA-based therapies and vector development has the potential to broaden the scope of targeted therapies, providing hope for patients with diseases for which no treatment currently exists.

Finally, this Special Issue also addresses the ethical, clinical, and technical challenges and ramifications associated with the clinical implementation of gene diagnostic and personalized therapies.

Guest Editor

Dr. Thomas Kitzler

Division of Medical Genetics, Department of Specialized Medicine, McGill University Health Centre, Montreal, QC H4A 3J1, Canada

Deadline for manuscript submissions

25 August 2025

GCAT
TACG
GCAT

Genes

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed

mdpi.com/si/217423

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

mdpi.com/journal/genes

MDPI

GCAT
TACG
GCAT

Genes

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed

mdpi.com/journal/genes

MDPI

About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Department of Pathology, The University of Alabama at Birmingham, 1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))